First Trust标普500经济护城河ETF EMOT 深 沪
等待开盘 05-22 09:30:00 美东时间
25.592
0.000
0.00%
华盛通- 最 高0.00
- 今 开25.592
- 成交量 3股
- 最 低 0.00
- 昨 收 25.592
- 总市值 255.93万
- 52周最高 25.592
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 21.7953
- 委 比 0.00%
- 总股本 10.00万
- 历史最高 25.592
- 量 比 0.04
- 振 幅 0.00%
- 历史最低 18.2795
- 每 手 1
- 风险率 0.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Roadzen Announces Partnership Between Its VehicleCare Platform And German Auto Parts Distributor TEMOT International
The opportunity is significant. India's motor insurance market reached approximately US$13.2 billion in gross written premiums in 2025 and is projected to grow to US$21.4 billion by 2030 at a 10.25% CAGR, according to
05-06 21:16
BRIEF-Daiichi Sankyo Co Ltd - Ifinatamab Deruxtecan Granted Priority Review In The U.S. For Adult Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression On Or After Platinum-Based Chemotherapy
BRIEF-Daiichi Sankyo Co Ltd - Ifinatamab Deruxtecan Granted Priority Review In The U.S. For Adult Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression On Or After Platinum-Based Chemotherapy April 14 (Reuters) - Daiichi Sankyo Co Ltd 4568.T : DA
04-14 09:14
BRIEF-Cytomx’S Varsetatug Masetecan (Epcam Probody® Adc) Continues To Demonstrate Positive Data Supporting Potential As A New Treatment Option In Late-Line Colorectal Cancer
BRIEF-Cytomx’S Varsetatug Masetecan (Epcam Probody® Adc) Continues To Demonstrate Positive Data Supporting Potential As A New Treatment Option In Late-Line Colorectal Cancer March 16 (Reuters) - CytomX Therapeutics Inc CTMX.O : CYTOMX’S VARSETATUG MASETECAN (EPCAM PROBODY® ADC) CONTINUES TO DEMONSTR
03-16 19:40
BRIEF-Nvidia Says Co Partnering With Venture Capital Firms Including Peak XV, Elevation Capital, Accel India & Others To Identify & Fund AI Startups
BRIEF-Nvidia Says Co Partnering With Venture Capital Firms Including Peak XV, Elevation Capital, Accel India & Others To Identify & Fund AI Startups Feb 17 (Reuters) - NVIDIA Corp NVDA.O : NVIDIA: TECH MAHINDRA DEPLOYING LARGE TELCO MODEL TO POWER AUTONOMOUS NETWORK OPERATIONS USING NVIDIA NIM NVIDI
02-18 08:30
BRIEF-ImmunityBio Launches Phase 2 Chemotherapy-Free Car-Nk Cell Therapy Trial With Anktiva
BRIEF-ImmunityBio Launches Phase 2 Chemotherapy-Free Car-Nk Cell Therapy Trial With Anktiva Feb 2 (Reuters) - Immunitybio Inc IBRX.O : IMMUNITYBIO LAUNCHES PHASE 2 CHEMOTHERAPY-FREE CAR-NK CELL THERAPY TRIAL WITH ANKTIVA® (RESQ215B) IN INDOLENT LYMPHOMAS Source text: ID:nBw3FxXx7a Further company co
02-02 21:03
BRIEF-Dogwood Therapeutics Reports Positive Interim Phase 2B Results In Chemotherapy-Induced Neuropathic Pain
Dec 22 (Reuters) - Dogwood Therapeutics Inc DWTX.O: DOGWOOD THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 2B CLINICAL TRIAL RESULTS IN CHEMOTHERAPY INDUCED NEUROPATHIC PAIN DOGWOOD THERAPEUTICS INC - ...
2025-12-23 01:16
BRIEF-Revolution Medicines Randomizes First Patient in Rasolute‑304 Trial
Dec 18 (Reuters) - Revolution Medicines Inc RVMD.O: REVOLUTION MEDICINES ANNOUNCES FIRST PATIENT RANDOMIZED IN THE RASOLUTE 304 CLINICAL TRIAL OF DARAXONRASIB IN RESECTABLE PANCREATIC DUCTAL ADENOCARC...
2025-12-18 21:28
BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint
Dec 17 (Reuters) - PFIZER: PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL & STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, & OVERALL SURVIVAL PFIZER: PATHOLOGIC COMPLETE RES...
2025-12-17 19:45
BRIEF-Nvidia Debuts Nemotron 3 Family Of Open Models
Dec 15 (Reuters) - NVIDIA Corp NVDA.O: NVIDIA DEBUTS NEMOTRON 3 FAMILY OF OPEN MODELS NVIDIA CORP - NEMOTRON 3 SUPER AND ULTRA EXPECTED IN FIRST HALF OF 2026 Source text: ID:nGNXb2cJTk Further company...
2025-12-16 00:29
美股异动 | 特斯拉大涨超4%股价逼近一年高位！AI概念股再度走弱，甲骨文、博通跌超2%
特斯拉大涨超4%逼近一年高位！马斯克称正在测试无人驾驶出租车；AI概念股再度走弱，甲骨文、博通跌超2%，现在服务重挫8%>>
2025-12-15 22:42
